132TiP Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC)

S Kasper,F Rivera,A.P Bento Pereira Da Silva,N.H Segal,P Deshpande,A St-Pierre,S Kopetz,C Tournigand,Y Cheng,N Amirouchene Angelozzi

doi:10.1016/j.annonc.2022.07.164

132TiP Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC)

S Kasper, F Rivera + Show 8 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.164

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

Affiliation: Marqués de Valdecilla University Hospital, Instituto de Investigación Marqués de Valdecilla, Novartis (Switzerland), Tris Pharma (United States), Novartis (United States), The University of Texas MD Anderson Cancer Center, Hôpitaux Universitaires Henri-Mondor

#Microsatellite-stable mCRC #Financial Interests + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

132TiP Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC)

Full Text